An Open Label, Randomized, Single Dose, 3-Way Crossover Study to Evaluate the Pharmacokinetics of Different Dose Levels and Dose Formulations of AM0010 in Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 29 May 2018
At a glance
- Drugs Ilodecakin (Primary)
- Indications Breast cancer; Colorectal cancer; Fibrosis; Hypercholesterolaemia; Inflammatory bowel diseases; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Renal cell carcinoma
- Focus Pharmacokinetics
- Acronyms Willow II
- Sponsors ARMO Biosciences
- 22 May 2018 Status changed from active, no longer recruiting to completed.
- 27 Mar 2018 Planned End Date changed from 9 Mar 2018 to 9 Apr 2018.
- 01 Feb 2018 Status changed from recruiting to active, no longer recruiting.